Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic Melanoma By Ogkologos - September 4, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1512 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Marine Runs Five Marathons in Five Days to Help Fund Sister’s... April 20, 2021 Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Three Brothers Under The Age Of 6 Are All Fighting The... February 7, 2020 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 Load more HOT NEWS The Largest Randomised Study to Date Points to Low Ipsilateral Breast... ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... Can Artificial Intelligence Help See Cancer in New, and Better, Ways? Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices...
